NVO
Novo-Nordisk A/S
$46.73
장중 · Vol 1.35M · 52주 $35.12–$64.16 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $44.99 · Aug 31, 2026
NVO 가격 추세
종가
$44.99
시가
$45.28
고가
$45.31
저가
$44.95
30초 브리핑
NVO 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 40%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 13.3배
선행 P/E가 높아 이익 둔화 또는 추정치 하향 가능성을 점검해야 합니다.
20일 평균의 1.0배
거래량은 최근 평균 범위입니다.
2026-11-04
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
NVO 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Alle 1 · Bagsvaerd, Denmark · 직원 66,700명
시가총액
$200.36B
Trailing P/E
11.1
최근 12개월 이익 기준
Forward P/E
13.3
이익 둔화 기대 반영
EPS (TTM)
$4.09
배당 수익률
3.96%
배당성향
44.5%
베타
0.35
시장보다 방어적
ROE
59.8%
P/B
5.82
EV/EBITDA
1.7
52주 범위
$35.12 – $64.16
현재 위치 40%
거래량
10.28M
20일 평균 10.69M · 1.0배
애널리스트 의견
매수 21%
총 14명 · 0m
DITM LEAPS Analysis
NVO 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVO280121C00025000 | 1/21/28 · 1.4Y | $25.00 | $21.67 | 1.9x | 0.9170 | 7.8% | 4.84% | 50.77% | 2,769 | 91.15 | |
| NVO271217C00025000 | 12/17/27 · 1.3Y | $25.00 | $21.63 | 1.9x | 0.9172 | 7.6% | 2.08% | 52.05% | 498 | 90.19 | |
| NVO271217C00030000 | 12/17/27 · 1.3Y | $30.00 | $17.65 | 2.2x | 0.8632 | 15.1% | 2.83% | 50.39% | 9,836 | 84.54 | |
| NVO271217C00027500 | 12/17/27 · 1.3Y | $27.50 | $19.45 | 2.1x | 0.8898 | 10.1% | 3.60% | 52.05% | 97 | 84.30 | |
| NVO280121C00027500 | 1/21/28 · 1.4Y | $27.50 | $19.78 | 2.0x | 0.8917 | 11.6% | 2.78% | 50.00% | 52 | 83.70 | |
| NVO280616C00025000 | 6/16/28 · 1.8Y | $25.00 | $22.07 | 1.8x | 0.8969 | 9.5% | 8.38% | 56.18% | 28 | 81.91 | |
| NVO280121C00030000 | 1/21/28 · 1.4Y | $30.00 | $17.97 | 2.1x | 0.8567 | 16.6% | 4.73% | 52.43% | 3,384 | 81.20 | |
| NVO270917C00030000 | 9/17/27 · 1.0Y | $30.00 | $16.97 | 2.3x | 0.8738 | 11.7% | 2.65% | 49.66% | 5 | 79.82 | |
| NVO280616C00027500 | 6/16/28 · 1.8Y | $27.50 | $20.38 | 1.9x | 0.8783 | 14.2% | 5.15% | 52.47% | 8 | 78.20 | |
| NVO270917C00032500 | 9/17/27 · 1.0Y | $32.50 | $15.08 | 2.5x | 0.8423 | 17.2% | 2.99% | 47.97% | 44 | 76.67 | |
| NVO280616C00030000 | 6/16/28 · 1.8Y | $30.00 | $18.63 | 2.1x | 0.8542 | 19.5% | 5.10% | 50.75% | 116 | 76.38 | |
| NVO280121C00032500 | 1/21/28 · 1.4Y | $32.50 | $16.25 | 2.3x | 0.8297 | 23.2% | 3.08% | 49.90% | 153 | 73.43 | |
| NVO270917C00035000 | 9/17/27 · 1.0Y | $35.00 | $13.30 | 2.7x | 0.8066 | 24.9% | 3.01% | 46.39% | 120 | 71.03 | |
| NVO280121C00035000 | 1/21/28 · 1.4Y | $35.00 | $14.63 | 2.5x | 0.7973 | 31.7% | 3.76% | 48.94% | 6,667 | 70.17 | |
| NVO271217C00032500 | 12/17/27 · 1.3Y | $32.50 | $15.87 | 2.4x | 0.8325 | 21.4% | 3.46% | 49.26% | 1 | 69.54 | |
| NVO271217C00035000 | 12/17/27 · 1.3Y | $35.00 | $14.35 | 2.5x | 0.7975 | 30.4% | 4.18% | 49.12% | 963 | 68.73 | |
| NVO280616C00032500 | 6/16/28 · 1.8Y | $32.50 | $16.97 | 2.2x | 0.8273 | 26.4% | 5.60% | 49.54% | 7 | 67.89 | |
| NVO280616C00035000 | 6/16/28 · 1.8Y | $35.00 | $15.42 | 2.3x | 0.7983 | 35.3% | 6.16% | 48.47% | 114 | 63.92 | |
| NVO271217C00037500 | 12/17/27 · 1.3Y | $37.50 | $12.75 | 2.7x | 0.7627 | 41.3% | 3.92% | 47.39% | 467 | 60.16 | |
| NVO280121C00037500 | 1/21/28 · 1.4Y | $37.50 | $13.13 | 2.6x | 0.7627 | 43.0% | 4.19% | 48.00% | 276 | 58.63 |
재무제표
NVO 연간 손익·현금흐름·재무상태
매출 성장률
+6.4%
최근 연간 YoY
EPS 성장률
+1.8%
최근 연간 YoY
영업이익률
41.3%
최근 연간
FCF 마진
9.4%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $309.06B+6.4% | $290.40B+25.0% | $232.26B+31.3% | $176.95B |
| 매출총이익 | $250.28B+1.8% | $245.88B+25.1% | $196.50B+32.3% | $148.51B |
| 영업이익 | $127.66B-0.5% | $128.34B+25.1% | $102.57B+37.1% | $74.81B |
| 순이익 | $102.43B+1.4% | $100.99B+20.7% | $83.68B+50.7% | $55.52B |
| 희석 EPS | $23.03+1.8% | $22.63+21.5% | $18.62+52.4% | $12.22 |
| EBITDA | $156.73B+5.9% | $147.94B+29.1% | $114.63B+49.3% | $76.80B |
| 영업현금흐름 | $119.10B-1.5% | $120.97B+11.1% | $108.91B+38.1% | $78.89B |
| 잉여현금흐름 | $28.99B-58.4% | $69.66B-0.5% | $70.01B+9.2% | $64.13B |
| 총자산 | $542.90B+16.6% | $465.63B+48.1% | $314.49B+30.4% | $241.26B |
| 총부채 | $130.96B+27.4% | $102.79B+280.6% | $27.01B+4.7% | $25.78B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
NVO 실적·배당 일정
매출 하단
$70.68B
EPS 하단
$4.68
매출 상단
$76.16B
배당 지급일
2026-08-25
7일 전
실적 발표일
2026-11-04
D-64
EPS 상단
$5.40
매출 컨센서스
$72.91B
EPS 컨센서스
$5.14
배당락일
2026-08-17
15일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 17, 2026 | $0.5790 |
| Mar 30, 2026 | $1.2750 |
| Aug 18, 2025 | $0.5840 |
| Mar 31, 2025 | $1.0990 |
| Aug 16, 2024 | $0.5130 |
| Mar 22, 2024 | $0.9300 |
| Aug 18, 2023 | $0.4420 |
| Mar 24, 2023 | $0.5945 |
뉴스
NVO 관련 최신 기사
제품·기술Chris Benecchi Named Inventiva’s New Chief Operating Officer
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.
Exec Edge · Aug 31, 2026
규제·법률LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
Zacks · Aug 31, 2026
규제·법률Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
Zacks · Aug 31, 2026
일반Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
Motley Fool · Aug 30, 2026
일반Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
Motley Fool · Aug 30, 2026
제품·기술Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.
Motley Fool · Aug 29, 2026
- 규제·법률
Novo's Wegovy Pill Enters China Behind Lilly
Regulatory acceptance opens the door, but it neither guarantees approval nor repairs Novo's late start.
GuruFocus.com · Aug 28, 2026
규제·법률Eli Lilly's diabetes drug Mounjaro gets approval for a new use
The FDA approved Eli Lilly's diabetes drug Mounjaro to cut down the risk of heart attack or stroke in high-risk adults with Type 2 diabetes.
USA TODAY · Aug 28, 2026
- 규제·법률
Mounjaro Just Opened a Much Bigger Door
A new FDA approval extends Lilly's blockbuster into cardiovascular risk reduction
GuruFocus.com · Aug 28, 2026
주주환원Accenture Stock And 2 Dividend Compounders for Passive Income
Central banks across Asia and Europe are moving toward tighter policy as inflation stays on the radar, yet cash in the bank still offers limited income. That gap creates a clear opening for investors who want income that can keep working even as rates shift. This article looks at three stocks from the Dividend Powerhouses screener that currently offer 5%+ yields with covered, growing, and stable payouts. The three dividend stocks covered below are just a small sample of this income theme, and...
Simply Wall St. · Aug 28, 2026
홀더
NVO 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
9.9%
기관 보유 (유동주식)
9.9%
내부자 보유
0.0%
기관 수
1,623
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Dodge & Cox Inc. | 20.40M | $924.60M | 0.6% | 5.5% | Jun 30, 2026 |
| LOOMIS SAYLES & CO L P | 18.59M | $842.88M | 0.5% | 9.3% | Jun 30, 2026 |
| Franklin Resources, Inc. | 13.04M | $591.15M | 0.4% | -18.9% | Jun 30, 2026 |
| Price (T.Rowe) Associates Inc | 11.70M | $530.57M | 0.3% | 5.8% | Jun 30, 2026 |
| Morgan Stanley | 11.66M | $528.54M | 0.3% | 7.3% | Jun 30, 2026 |
| Bank of America Corporation | 11.18M | $506.64M | 0.3% | 3.8% | Jun 30, 2026 |
| Capital International Investors | 9.72M | $440.66M | 0.3% | -17.6% | Jun 30, 2026 |
| Folketrygdfondet | 9.52M | $431.65M | 0.3% | 4.9% | Jun 30, 2026 |
| Goldman Sachs Group Inc | 9.18M | $416.15M | 0.3% | 79.3% | Jun 30, 2026 |
| Fisher Asset Management, LLC | 8.32M | $377.37M | 0.3% | -7.7% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.
